
Chinese oncology company within the Simcere Pharmaceutical group, founded in 2020 and operating independently since 1 January 2023, working on development and commercialisation of innovative anticancer medicines. Aims to address large unmet clinical needs in oncology worldwide through its own research and collaboration with partners, has launched several innovative products in China including Cosela, Envafolimab, Endostar and Enlituo, and has raised about 134 million US dollars in total funding. Its group registration is held through Hainan Simcere Zaiming Pharmaceutical, incorporated on 3 December 2020 with about 458.9 million yuan of registered capital and Tang Renhong as legal representative.
評価を残す